Natural Pharmatech enters Japan en-route to the US

By Kirsty Barnes

- Last updated on GMT

Related tags: Pharmacology

China-based Natural Pharmatech has formed its first research
contract with a Japanese company, Kobayashi Pharmaceutical -
another step forward in Natural Pharmatech's plans to bring its
botanical R&D services to the global stage.

Under the contract, Natural Pharmatech will provide pre-clinical pharmacology and toxicology testing services for Kobayashi's botanical drug development program, at a more competetive cost than companies in Japan, said the firm.

The deal stems from Natural Pharmatech's recent efforts to expand its services into other countries. Initial efforts have so far focused on China's neighbouring regions, such as Malaysia, Singapore, Indonesia, Hong Kong and Japan.

However, the company has its sights set firmly on cracking the US market and the firm, set up by US company, Global Pharmatech for this very purpose, already has its foot firmly in the door.

In addition to R&D services, the company plans to develop its own botanical drugs to distribute throughout the US, and will test the waters later this year with the launch of its dietary supplements.

A botanical drug differs from a chemical-based drug in that its active ingredient is extracted from a herb, rather than chemically formulated.

"China has 5,000 years of clinical experience with herbs that are known to cure diseases. These herbs are now being put into pills to be made more acceptable to consumers in today's drug market,"​ Zhuojun Li, Investor Relations, Global Pharmatech, told

Botanical drugs are big business in china, and other Asian countries, with one quarter of all drug sales in China coming from this market segment.

However, the market is only just beginning to take off in the US after the Food and Drug Administration (FDA) recently passed a guidance on the development of such drugs.

"Botanical drugs have enormous potential in today's drug market. Because they are natural, they have many advantages, including fewer side-effects,"​ said Li.

This means that they can be particularly useful in treating chronic illnesses, a major unmet need in many disease areas in the Western pharma market.

Related products

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more